Advertisement
UK markets closed

  • FTSE 100

    7,895.85
    +18.80 (+0.24%)
     

  • FTSE 250

    19,391.30
    -59.37 (-0.31%)
     

  • AIM

    745.67
    +0.38 (+0.05%)
     

  • GBP/EUR

    1.1607
    -0.0076 (-0.65%)
     

  • GBP/USD

    1.2369
    -0.0069 (-0.56%)
     

  • Bitcoin GBP

    51,632.70
    +332.37 (+0.65%)
     

  • CMC Crypto 200

    1,381.82
    +69.20 (+5.27%)
     

  • S&P 500

    4,967.23
    -43.89 (-0.88%)
     

  • DOW

    37,986.40
    +211.02 (+0.56%)
     

  • CRUDE OIL

    83.44
    +0.71 (+0.86%)
     

  • GOLD FUTURES

    2,403.40
    +5.40 (+0.23%)
     

  • NIKKEI 225

    37,068.35
    -1,011.35 (-2.66%)
     

  • HANG SENG

    16,224.14
    -161.73 (-0.99%)
     

  • DAX

    17,737.36
    -100.04 (-0.56%)
     

  • CAC 40

    8,022.41
    -0.85 (-0.01%)
     
Property:

11 beautiful homes with glorious garden rooms

Investing in a home with a garden room will enable you to enjoy your outside space whatever the weather

AstraZeneca's Tagrisso to cost $12,750 for a month's supply

Reuters - UK Focus

(Updates detail on comparable drugs, link to Clovis story)

LONDON, Nov 17 (Reuters) - AstraZeneca (NYSE: AZN - news) 's new lung cancer pill Tagrisso, which won early U.S (Other OTC: UBGXF - news) . approval on Friday, will cost $12,750 for a month's supply.

A company spokeswoman said on Tuesday the wholesale acquisition cost was comparable to other targeted oral lung cancer therapies, such as Pfizer (NYSE: PFE - news) 's Xalkori and Novartis (LSE: 0QLR.L - news) ' Zykadia.

AstraZeneca has previously said it believes Tagrisso could generate peak sales of $3 billion a year, making it a key product in the group's growing oncology portfolio.

Its prospects received a boost on Monday when a rival drug from Clovis Oncology (Xetra: C6O.DE - news) hit a snag, with U.S. health regulators asking for more data and Clovis reporting lower-than-expected confirmed response rates. (Reporting by Ben Hirschler; editing by Jason Neely)